A closer look at “From CDK9 Discovery to Precision Medicine: The Next Generation of Cancer Cell Cycle Therap”, exactly as the source publishes it. More than three decades after scientists linked the cell cycle's molecular machinery to cancer, a new review traces the evolution of cyclin-dependent kinase (CDK) research and outlines what's next for CDK-targeted therapies. The paper highlights the journey from the discovery of CDK9 to today's precision medicine approaches, underscoring how these enzymes have become pivotal drug targets in oncology. Key milestones include the development of CDK4/6 inhibitors, which have transformed treatment for hormone receptor-positive breast cancer, and ongoing efforts to target other CDKs like CDK9 for hematologic malignancies.
The review emphasizes the need for biomarkers to select patients most likely to benefit and explores combination strategies to overcome resistance. As research advances, the next generation of CDK inhibitors aims to improve efficacy and reduce toxicity, offering hope for broader cancer applications. The full version stays on the original page, which this listing opens directly.